Small molecules targeting JAKs-a new approach in the treatment of rheumatoid arthritis

被引：23

作者：

Feist, Eugen ^{[1
,2
]}

Burmester, Gerd R. ^{[1
,2
]}

机构：

[1] Free Univ Berlin, Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, D-10117 Berlin, Germany

[2] Univ Berlin, D-10117 Berlin, Germany

来源：

RHEUMATOLOGY | 2013年 / 52卷 / 08期

关键词：

rheumatoid arthritis; tofacitinib; fostamatinib; janus kinase; INHIBITOR; CP-690,550; TOFACITINIB; PLACEBO; REJECTION; TRIAL;

D O I：

10.1093/rheumatology/kes417

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Advances in the treatment of RA in the past decade have been achieved mainly by using combinations of different conventional and biologic DMARDs. However, until now no final victory has been achieved over this organ damaging and potentially life-threatening systemic autoimmune disease. Few patients, notably those with established disease, stay in remission permanently, even using advanced treatment concepts. Thus novel approaches, especially for patients resistant to biologics, are urgently needed. Pro-inflammatory signalling pathways beyond the level of cytokines and receptors have been intensively elaborated and provide such potential targets. This review focuses on the development of new small molecule inhibitors of Janus kinases in clinical trials in RA.

引用

页码：1352 / 1357

页数：6

共 15 条

[1]

[Anonymous], 2012, ADV COMM M TOF TREAT

[2]

Burmester GR, 2013, LANCET

[3]

Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor [J].

Changelian, PS ;

Flanagan, ME ;

Ball, DJ ;

Kent, CR ;

Magnuson, KS ;

Martin, WH ;

Rizzuti, BJ ;

Sawyer, PS ;

Perry, BD ;

Brissette, WH ;

McCurdy, SP ;

Kudlacz, EM ;

Conklyn, MJ ;

Elliott, EA ;

Koslov, ER ;

Fisher, MB ;

Strelevitz, TJ ;

Yoon, K ;

Whipple, DA ;

Sun, JM ;

Munchhof, MJ ;

Doty, JL ;

Casavant, JM ;

Blumenkopf, TA ;

Hines, M ;

Brown, MF ;

Lillie, BM ;

Subramanyam, C ;

Shang-Poa, C ;

Milici, AJ ;

Beckius, GE ;

Moyer, JD ;

Su, CY ;

Woodworth, TG ;

Gaweco, AS ;

Beals, CR ;

Littman, BH ;

Fisher, DA ;

Smith, JF ;

Zagouras, P ;

Magna, HA ;

Saltarelli, MJ ;

Johnson, KS ;

Nelms, LF ;

Des Etages, SG ;

Hayes, LS ;

Kawabata, TT ;

Finco-Kent, D ;

Baker, DL ;

Larson, M .

SCIENCE, 2003, 302 (5646) :875-878

[4]

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection [J].

Flanagan, Mark E. ;

Blumenkopf, Todd A. ;

Brissette, William H. ;

Brown, Matthew F. ;

Casavant, Jeffrey M. ;

Shang-Poa, Chang ;

Doty, Jonathan L. ;

Elliott, Eileen A. ;

Fisher, Michael B. ;

Hines, Michael ;

Kent, Craig ;

Kudlacz, Elizabeth M. ;

Lillie, Brett M. ;

Magnuson, Kelly S. ;

McCurdy, Sandra P. ;

Munchhof, Michael J. ;

Perry, Bret D. ;

Sawyer, Perry S. ;

Strelevitz, Timothy J. ;

Subramanyam, Chakrapani ;

Sun, Jianmin ;

Whipple, David A. ;

Changelian, Paul S. .

JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (24) :8468-8484

[5]

Fleischmann R, ACR2011

[6]

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis [J].

Fleischmann, Roy ;

Kremer, Joel ;

Cush, John ;

Schulze-Koops, Hendrik ;

Connell, Carol A. ;

Bradley, John D. ;

Gruben, David ;

Wallenstein, Gene V. ;

Zwillich, Samuel H. ;

Kanik, Keith S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (06) :495-507

[7]

Kinase Inhibition - A New Approach to the Treatment of Rheumatoid Arthritis [J].

Fox, David A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (06) :565-567

[8]

A quantitative analysis of kinase inhibitor selectivity [J].

Karaman, Mazen W. ;

Herrgard, Sanna ;

Treiber, Daniel K. ;

Gallant, Paul ;

Atteridge, Corey E. ;

Campbell, Brian T. ;

Chan, Katrina W. ;

Ciceri, Pietro ;

Davis, Mindy I. ;

Edeen, Philip T. ;

Faraoni, Raffaella ;

Floyd, Mark ;

Hunt, Jeremy P. ;

Lockhart, Daniel J. ;

Milanov, Zdravko V. ;

Morrison, Michael J. ;

Pallares, Gabriel ;

Patel, Hitesh K. ;

Pritchard, Stephanie ;

Wodicka, Lisa M. ;

Zarrinkar, Patrick P. .

NATURE BIOTECHNOLOGY, 2008, 26 (01) :127-132

[9]

Keystone E, EULAR 2012 BERL

[10]

The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo [J].

Kremer, Joel M. ;

Bloom, Bradley J. ;

Breedveld, Ferdinand C. ;

Coombs, John H. ;

Fletcher, Mark P. ;

Gruben, David ;

Krishnaswami, Sriram ;

Burgos-Vargas, Ruben ;

Wilkinson, Bethanie ;

Zerbini, Cristiano A. F. ;

Zwillich, Samuel H. .

ARTHRITIS AND RHEUMATISM, 2009, 60 (07) :1895-1905

← 1 2 →